Benzinga's Top Downgrades - AMTD IDEA Group (NYSE:AMTD), Barclays (NYSE:BCS)

Analysts at Goldman Sachs downgraded Barclays PLC (ADR) BCS from Buy to Neutral. Barclays shares rose 3.56 percent to $7.28 in pre-market trading.
Analysts at Argus Research downgraded Tesla Motors Inc TSLA from Buy to Hold. Tesla shares gained 1.23 percent to $201.00 in pre-market trading.
RBC Capital downgraded UBS Group AG (USA) UBS from Sector Perform to Underperform. UBS shares gained 0.08 percent to $12.82 in pre-market trading.
Bank of America downgraded TD Ameritrade Holding Corp. AMTD from Buy to Neutral. TD Ameritrade shares rose 1.95 percent to $27.20 in pre-market trading.
JP Morgan downgraded Dow Chemical Co DOW from Overweight to Neutral. Dow Chemical shares rose 1.06 percent to $50.50 in pre-market trading.
Analysts at SunTrust Robinson Humphrey downgraded HeartWare International Inc HTWR from Buy to Neutral. Heartware shares rose 0.17 percent to $57.89 in pre-market trading.
KeyBanc downgraded Penske Automotive Group, Inc. PAG from Overweight to Sector Perform. Penske Automotive shares declined 0.38 percent to $31.60 in pre-market trading.
Bank of America downgraded Och-Ziff Capital Management Group LLC OZM from Buy to Neutral. Och-Ziff Capital shares fell 0.26 percent to $3.80 in pre-market trading.
Analysts at Piper Jaffray downgraded Navistar International Corp NAV from Overweight to Neutral. Navistar shares gained 0.09 percent to $10.88 in pre-market trading.
BMO Capital downgraded Regulus Therapeutics Inc RGLS from Outperform to Market Perform. The price target for Regulus Therapeutics has been lowered from $16 to $4. Regulus Therapeutics shares fell 51.30 percent to $2.44 in pre-market trading.

Market News and Data brought to you by Benzinga APIs